Celldex's barzolvolimab failed all efficacy measures in a Phase 2 prurigo nodularis trial, focus shifts to two Phase 3 trials for chronic spontaneous urticaria.
Anthony Marucci, Celldex CEO
July 22, 2026 06:49 AM EDT
Celldex scraps antibody in itchy skin nodules after Phase 2 flop
Celldex said on Tuesday it will stop investigating its mast cell-targeting monoclonal antibody in a type of chronic itch disease after it failed on all …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Celldex has discontinued its Phase 2 trial of barzolvolimab for prurigo nodularis after failing to meet primary and secondary…
CLEVELAND — After more than a decade with no new medications for chronic spontaneous urticaria, clinicians are beginning to see…
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in…
Sanofi has decided it won’t seek an approval in atopic dermatitis for amlitelimab, the OX40-ligand antibody it had hoped would be…
Merck ends a Phase 2 Alzheimer's trial for MK-1167, partnered with Neuphoria Therapeutics, after the drug missed efficacy…
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster.…
